Hepatocyte nuclear factor-1-beta (HNF1B) is a transcription factor crucial for the development of several tissues, and a promising biomarker of certain solid tumours. Thus far, two HNF1B alternative splicing variants (ASVs) have been described, however, the complete spectrum, prevalence and role of HNF1B ASVs in tumorigenesis are unclear. Considering the equivocal data about HNF1B ASVs and expression presented in literature, our aim was to characterize the spectrum of HNF1B mRNA splicing variants across different tissues. Here, we characterize HNF1B ASVs with high sensitivity in carcinomas of the uterine corpus, large intestine, kidney, pancreas, and prostate, with selected paired healthy tissues, using the previously described multiplex PCR and NGS approach. We identified 45 ASVs, of which 43 were novel. The spectrum and relative quantity of expressed ASVs mRNA differed among the analysed tissue types. Two known (3p, Δ7_8) and two novel (Δ7, Δ8) ASVs with unknown biological functions were detected in all the analysed tissues in a higher proportion. Our study reveals the wide spectrum of HNF1B ASVs in selected tissues. Characterization of the HNF1B ASVs is an important prerequisite for further expression studies to delineate the HNF1B splicing pattern, potential ASVs functional impact, and eventual refinement of HNF1B's biomarker role.

1st Department of Surgery Department of Abdominal Thoracic Surgery and Traumatology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague 12808 Czech Republic

Department of Urology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague 12808 Czech Republic

Gynecological Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague 12851 Czech Republic

Institute of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University Prague 12853 Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague 12808 Czech Republic

Zobrazit více v PubMed

Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 1996;10:267–282. doi: 10.1096/fasebj.10.2.8641560. PubMed DOI

Bartu M, et al. The Role of HNF1B in Tumourigenesis of Solid Tumours: a Review of Current Knowledge. Folia Biol. 2018;64:71–83. PubMed

Yu DD, Guo SW, Jing YY, Dong YL, Wei LX. A review on hepatocyte nuclear factor-1beta and tumour. Cell Biosci. 2015;5:58. doi: 10.1186/s13578-015-0049-3. PubMed DOI PMC

El-Khairi R, Vallier L. The role of hepatocyte nuclear factor 1beta in disease and development. Diabetes Obes. Metab. 2016;18(Suppl 1):23–32. doi: 10.1111/dom.12715. PubMed DOI

Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J. Am. Soc. Nephrol. 2000;11(Suppl 16):S140–143. PubMed

Suzuki E, et al. Transcriptional upregulation of HNF-1beta by NF-kappaB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Lab. Invest. 2015;95:962–972. doi: 10.1038/labinvest.2015.73. PubMed DOI

Tsuchiya A, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003;163:2503–2512. doi: 10.1016/S0002-9440(10)63605-X. PubMed DOI PMC

Fagerberg L, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell Proteom. 2014;13:397–406. doi: 10.1074/mcp.M113.035600. PubMed DOI PMC

Adalat S, et al. HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J. Am. Soc. Nephrol. 2009;20:1123–1131. doi: 10.1681/ASN.2008060633. PubMed DOI PMC

Anik A, Catli G, Abaci A, Bober E. Maturity-onset diabetes of the young (MODY): an update. J. Pediatr. Endocrinol. Metab. 2015;28:251–263. doi: 10.1515/jpem-2014-0384. PubMed DOI

Buchner A, et al. Downregulation of HNF-1B in renal cell carcinoma is associated with tumour progression and poor prognosis. Urology. 2010;76(507):e506–511. doi: 10.1016/j.urology.2010.03.042. PubMed DOI

Nemejcova K, et al. Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions. Pathol. Oncol. Res. 2016;22:523–530. doi: 10.1007/s12253-015-0037-2. PubMed DOI

Silva TD, et al. DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol. Lett. 2013;6:1687–1692. doi: 10.3892/ol.2013.1606. PubMed DOI PMC

Matsui A, et al. Hepatocyte nuclear factor 1 beta induces transformation and epithelial-to-mesenchymal transition. FEBS Lett. 2016;590:1211–1221. doi: 10.1002/1873-3468.12147. PubMed DOI

Zheng KL, et al. Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma. Int. J. Clin. Exp. Pathol. 2015;8:6181–6191. PubMed PMC

Paschalis A, et al. Alternative splicing in prostate cancer. Nat. Rev. Clin. Oncol. 2018;15:663–675. doi: 10.1038/s41571-018-0085-0. PubMed DOI

Sevcik J, et al. The BRCA1 alternative splicing variant Delta14-15 with an in-frame deletion of part of the regulatory serine-containing domain (SCD) impairs the DNA repair capacity in MCF-7 cells. Cell Signal. 2012;24:1023–1030. doi: 10.1016/j.cellsig.2011.12.023. PubMed DOI

Sevcik J, et al. Expression of human BRCA1Delta17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response. Cell Signal. 2013;25:1186–1193. doi: 10.1016/j.cellsig.2013.02.008. PubMed DOI

Ross-Adams H, et al. HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget. 2016;7:74734–74746. doi: 10.18632/oncotarget.12543. PubMed DOI PMC

Pickrell JK, Pai AA, Gilad Y, Pritchard JK. Noisy splicing drives mRNA isoform diversity in human cells. PLoS Genet. 2010;6:e1001236. doi: 10.1371/journal.pgen.1001236. PubMed DOI PMC

Harries LW, Brown JE, Gloyn AL. Species-specific differences in the expression of the HNF1A, HNF1B and HNF4A genes. PLoS One. 2009;4:e7855. doi: 10.1371/journal.pone.0007855. PubMed DOI PMC

Harries LW, Perry JR, McCullagh P, Crundwell M. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer. 2010;10:315. doi: 10.1186/1471-2407-10-315. PubMed DOI PMC

Carithers LJ, et al. A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. Biopreserv Biobank. 2015;13:311–319. doi: 10.1089/bio.2015.0032. PubMed DOI PMC

Kornblihtt AR, et al. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat. Rev. Mol. Cell Biol. 2013;14:153–165. doi: 10.1038/nrm3525. PubMed DOI

El Marabti E, Younis I. The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer. Front. Mol. Biosci. 2018;5:80. doi: 10.3389/fmolb.2018.00080. PubMed DOI PMC

Bustin SA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009;55:611–622. doi: 10.1373/clinchem.2008.112797. PubMed DOI

Hojny J, et al. Multiplex PCR and NGS-based identification of mRNA splicing variants: Analysis of BRCA1 splicing pattern as a model. Gene. 2017;637:41–49. doi: 10.1016/j.gene.2017.09.025. PubMed DOI

Robinson JT, et al. Integrative genomics viewer. Nat. Biotechnol. 2011;29:24–26. doi: 10.1038/nbt.1754. PubMed DOI PMC

Renal and Extrarenal Phenotypes in Patients With HNF1B Variants and Chromosome 17q12 Microdeletions

Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases

Comprehensive quantitative analysis of alternative splicing variants reveals the HNF1B mRNA splicing pattern in various tumour and non-tumour tissues

HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study